Intervet Receives FDA Approval for Zilmax
21 August 2006
Boxmeer, The Netherlands
Intervet’s U.S. business (Intervet Inc.) has received approval from the U.S. Food and Drug Administration (FDA) for Zilmax (zilpaterol hydrochloride), a product designed to improve production efficiencies in beef cattle during the last phase of the feeding period.
The results of the U.S. studies confirmed the safety and efficacy that Intervet has experienced with Zilmax through more than 10 years of international use.
Commercialization will begin in 2007 following completion of additional studies designed to define optimal usage recommendations under the unique U.S. cattle feeding and marketing conditions.
Intervet Inc. (www.intervetusa.com) is an affiliate of Intervet International bv. Intervet is a leading global supplier of beef production technologies and maintains an intensive research and development effort in this field. Zilmax is the latest innovation demonstrating Intervet’s commitment to health and performance technologies that benefit the beef industry.
- - - - -
Note for the editor
Intervet, a business unit of Akzo Nobel, based in Boxmeer, the Netherlands, with sales of EUR 1,094 million in 2005, is dedicated to research and development, production and marketing of innovative animal health products. Intervet's product range for use in livestock, companion animals, poultry and fish includes vaccines, antiparasitics, anti-infectives, endocrine products and other pharmaceutical specialties. Intervet operates globally with its own marketing organizations. The company currently employs around 5,000 people.
Internet: www.intervet.com
Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,500 people and conduct our activities in four segments - human and animal health, coatings and chemicals - subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the third quarter will be published on October 18, 2006.
Internet: www.akzonobel.com
